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Abstract
Vascular endothelial (VE) cadherin is a key component of endothelial adherens junctions (AJs) and plays an important 
role in maintaining vascular integrity. Endocytosis of VE-cadherin regulates junctional strength and a decrease of surface 
VE-cadherin reduces vascular stability. However, disruption of AJs is also a requirement for vascular sprouting. Identify-
ing novel regulators of endothelial endocytosis could enhance our understanding of angiogenesis. Here, we evaluated the 
angiogenic potential of (CKLF-like MARVEL transmembrane domain 4) CMTM4 and assessed in which molecular pathway 
CMTM4 is involved during angiogenesis. Using a 3D vascular assay composed of GFP-labeled HUVECs and dsRED-labeled 
pericytes, we demonstrated in vitro that siRNA-mediated CMTM4 silencing impairs vascular sprouting. In vivo, CMTM4 
silencing by morpholino injection in zebrafish larvae inhibits intersomitic vessel growth. Intracellular staining revealed that 
CMTM4 colocalizes with  Rab4+ and  Rab7+ vesicles, both markers of the endocytic trafficking pathway. CMTM4 colocal-
izes with both membrane-bound and internalized VE-cadherin. Adenovirus-mediated CMTM4 overexpression enhances the 
endothelial endocytic pathway, in particular the rapid recycling pathway, shown by an increase in early endosomal antigen-1 
positive  (EEA1+),  Rab4+,  Rab11+ , and  Rab7+ vesicles. CMTM4 overexpression enhances membrane-bound VE-cadherin 
internalization, whereas CMTM4 knockdown decreases internalization of VE-cadherin. CMTM4 overexpression promotes 
endothelial barrier function, shown by an increase in recovery of transendothelial electrical resistance (TEER) after throm-
bin stimulation. We have identified in this study a novel regulatory function for CMTM4 in angiogenesis. CMTM4 plays an 
important role in the turnover of membrane-bound VE-cadherin at AJs, mediating endothelial barrier function and control-
ling vascular sprouting.
Keywords Endothelial cells · Angiogenesis · Adherens junctions · VE-cadherin · CMTM4
Introduction
Angiogenesis is a critical process that occurs during embry-
onic development, is re-activated in wound healing, and is 
often disturbed in disease. Abnormalities in new vessel 
formation, represented by either excessive or insufficient 
growth, contribute to a wide range of disorders, including 
cancer and cardiovascular diseases [1].
Acquiring and maintaining vascular homeostasis is cru-
cial for the formation and stabilization of new blood ves-
sels during angiogenesis. In order for the endothelial cells 
(ECs), that form the inner lining of new blood vessels, to 
function in an integrated manner, specific junctions con-
sisting of cell adhesion molecules are required. From these 
junctions, adherens junctions (AJs) are critical for cell–cell 
adhesion and are tightly regulated by complex molecular 
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pathways. Vascular endothelial (VE) cadherin is the main 
cell adhesion molecule found in endothelial AJs and plays 
an important role in maintaining endothelial barrier func-
tion [2, 3]. Blocking VE-cadherin by the use of antibodies 
has a negative effect on endothelial survival and increases 
vascular permeability [4]. In addition, VE-cadherin-deficient 
mice suffer from severe vascular defects, including impaired 
vascular sprouting, limited organization of ECs into large 
mature vessels, and vessel regression, resulting in death at 
mid-gestation [5, 6].
AJs are dynamic structures from which the amount of 
membrane-bound VE-cadherin that can undergo homophilic 
interactions with neighboring cells can be actively regu-
lated, thereby modulating the junctional adhesive strength. 
A reduction in membrane-bound VE-cadherin will result 
in microvascular destabilization and loss of barrier func-
tion. However, a decrease in adhesive strength is required 
for the disruption of AJs in order to allow EC migration 
and morphological adaptation into tip and stalk cells during 
vascular sprouting.
Endocytosis is a form of active transport that is com-
monly used by cells to take up large secreted molecules or 
membrane-bound proteins, such as VE-cadherin, into the 
cytosol for processing. VE-cadherin is taken up in special-
ized regions called clathrin-coated pits that bud from the 
membrane to form clathrin-coated vesicles. These vesicles 
then fuse with early endosomes in which the endocytosed 
cargo is sorted for recycling, lysosomal, or other trafficking 
routes [7]. Each distinct trafficking step is controlled by a 
subset of Rab GTPases, making these enzymes ideal markers 
to monitor the transport route of endocytosed proteins [8]. 
Rapid endocytosis of VE-cadherin and the subsequent disas-
sembly of AJs is promoted by vascular endothelial growth 
factor A (VEGFA), making the ligand for the VEGF Recep-
tor 1 and 2 (VEGFR1 and 2) an active regulator of vascular 
permeability [9].
Whereas endocytosis plays a vital role in modulating vas-
cular permeability by controlling the adhesive strength in 
AJs, little is known about important regulators involved in 
the early endocytic and subsequent trafficking routes in ECs. 
Moreover, the exact contribution of endocytosis regulators 
to the angiogenic process remains to be further elucidated. 
To identify novel regulators of angiogenesis, we performed 
a transcriptome analysis of mouse embryos, comparing 
 VEGFR2+ endothelial progenitor cells with the VEGFR2-
negative cell population. We identified an enriched expres-
sion of several members of the CKLF-like Marvel Trans-
membrane Domain-containing gene (CMTM) family in the 
 VEGFR2+ population. In humans, this family comprises 9 
genes (CKLF and CMTM1-8) that all contain a MAL (myo-
sin and lymphocyte) And Related proteins for Vesicle traf-
ficking and membrane Link (MARVEL) domain [10]. Sev-
eral studies on CMTM members reveal that they can prevent 
growth and invasion of different cancer types [11–18]. In a 
recent study, we revealed that CMTM3 has a specialized 
function in ECs, where it is involved in regulating the early 
endocytosis of VE-cadherin during vascular growth [19]. 
However, the putative function of other CMTM members in 
endothelial endocytosis, regulation of vascular permeability, 
and angiogenesis remains to be elucidated. Increasing our 
understanding of other regulators of angiogenesis is highly 
important for the development of novel therapeutic targets.
In this study, we investigated the angiogenic potential 
of CMTM4 and assessed in which molecular pathways 
CMTM4 is involved in ECs. To our knowledge, CMTM4 
is until now only known for its potential to act as a tumor 
suppressor gene [14]. Our data demonstrated that CMTM4 
regulates angiogenesis by promoting cell surface recycling 
of VE-cadherin to endothelial AJs.
Materials and methods
Cell culture
Primary human umbilical vein endothelial cells (HUVECs) 
were purchased from Lonza and maintained in EGM2 
medium (Lonza) with 100  Uml−1 penicillin-streptomy-
cin (PS). Primary human brain-derived vascular peri-
cytes were purchased from ScienCell and maintained in 
DMEM + 10%  FCS with 100  Uml−1 PS. At passage 1, 
HUVECs were transduced with lentiviral GFP construct 
(HUVECs-GFP) and pericytes with lentiviral dsRED 
construct (pericytes-dsRED) and selected for puromycin 
(2.5 ug/ml) resistance as previously described [19]. All cells 
were used between passages 3 and 6 and cultured at 37 °C in 
a humidified atmosphere containing 5%  CO2.
qPCR analysis
Total RNA was isolated from cultures (single-cell monolay-
ers and co-cultured HUVECs and pericytes) using RNeasy 
kit (Qiagen) according to the manufacturer’s instructions. 
The purity and concentrations of RNA were quantified by 
using Nanodrop (ND-1000) absorbance measurements at 
260/280 nm and/or capillary electrophoresis (Agilent 2100 
Bioanalyser). The iScript synthesis kit (Biorad) was used 
for cDNA synthesis according to the manufacturer’s instruc-
tions. Gene expression was determined using quantitative 
real-time PCR (qPCR) according to the SYBR-Green-Cycler 
IQ5 detection protocol (Biorad). The primer sequences are 
listed in Supplementary Table 1. All results were normalized 
for the expression of house-keeping gene β-actin.
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Short interference RNA (siRNA)
CMTM4 or CMTM3 knockdown in HUVECs and 
HUVECs-GFP was achieved by using either a mix of 4 
complementary siRNA sequences or 2 sets of individual 
siRNA sequences directed against the mRNA of CMTM4 
or CMTM3 (ThermoScientific). As a negative control, cells 
were either untreated or transfected with a mix of 4 non-
targeting siRNA sequences. The sequences are listed in Sup-
plementary Table 2.
Adenoviral transduction
Human recombinant CMTM4 or CMTM3 adenovirus were 
produced using the Gateway pAd/CMV/V5-DEST vector 
kit and ViraPower™ Adenoviral Expression System kit, 
according to the manufacturer’s instructions (Invitrogen). 
Fully sequenced Human CMTM4 or CMTM3 cDNA were 
obtained from OriGene and Lifesciences, respectively, 
cloned in a pCMV-SPORT6 vector. To amplify the CMTM4 
gene from the obtained clone and simultaneously convert 
it with attB sites, a PCR was conducted with full-length 
attB-CMTM4-specific primers: forward oligo’s 5′- GGG 
GAC AAG TTT GTA CAA AAA AGC AGG CTT CAC CAT 
GCG GAG CGG CGA GGA GCT GGA CGG -3′ and reverse 
oligo’s 5′- GGG GAC CAC TTT GTA CAA GAA AGC TGG 
GTT TCA CGT GTC CAG GCG CTG GAT CTC AGG-3′. The 
full-length attB-CMTM4 amplicons was then cloned into a 
pDONR™ 221 vector to create an entry clone, according to 
BP Clonase™ II protocol. Full-length cDNAs of CMTM3 
with attB-site was amplified by PCR using specific forward 
oligos 5′- GGG GAC AAG TTT GTA CAA AAA AGC AGG 
CTT CAC CAT GTG GCC CCC AGA CCC CGA CC-3′ and 
reverse oligo’s 5′- GGG GAC CAC TTT GTA CAA GAA AGC 
TGG GTT TCA GTC AGA GTC CGA GTC GGA ATT CTC-3′. 
Moreover a HIS tag was placed at the C-terminal region 
of CMTM3 (CMTM3-HA) using the RV primer 5′- GGG 
GAC CAC TTT GTA CAA GAA AGC T GGG TGG TCA GAG 
TCC GAG TCG GAA TTCTC-3′. Amplicons of CMTM3 
and CMTM3-HA were cloned into a pDONRTM 221 vec-
tor via BP ClonaseTM II enzyme mix to create an entry 
clone. DNA sequencing validated the obtained CMTM4 or 
CMTM3 sequence. Using LR-reaction II (Invitrogen), the 
CMTM4 or CMTM3 reading frame cassettes were cloned 
into pAd/CMV/V5-DEST (Invitrogen) expression vectors 
according to the manufacturer’s protocol. After verification 
by DNA sequencing, the pAd/CMV/V5-DEST plasmids 
were linearized by Pac1 restriction and transfected with 
Lipofectamine 2000 (Invitrogen) into 293A cells. When 80% 
of the infected cells formed crude viral vesicles, the cells 
were harvested, followed by three cycles of freeze/thawing 
to get crude viral lysate (CVL), and the virus was purified 
using cesium chloride gradient.
Subcellular fractioning and protein extraction
To separate cytoplasmic proteins from the membrane-bound 
proteins, i.e., the soluble and insoluble fraction, respectively, 
HUVECs received a PBS wash twice and were harvested 
in lysis buffer [140 mM NaCl, 10 mM Tris (pH 7.6), 1 mM 
EDTA, 1% Triton X-100, 0.05% SDS, 1X protease inhibitor 
cocktail, 1 mM PMSF] 48-h post-transfection. The lysates 
were incubated on ice for 20 min and were centrifuged at 
13,000 g for 12 min to separate the soluble from the insolu-
ble fraction. The pellet was then solubilized in lysis buffer 
with 2% SDS. Both fractions were subjected to SDS–PAGE 
and immunoblotting.
Western blot
Protein concentration was determined by the Bradford 
method (Pierce BCA Protein Assay kit). Equal amounts of 
sample were loaded on a sodium dodecyl sulfate–polyacryla-
mide gel electrophoresis (SDS–PAGE) and transferred onto 
a nitrocellulose membrane (Pierce) at 4 °C overnight. Mem-
branes were blocked and probed with primary antibodies 
according to the manufacturer’s instructions (Supplementary 
Table 3). Protein bands were visualized with Li-Cor second-
ary antibodies and detection system (Westburg) according to 
the manufacturer’s instructions. The detected protein expres-
sions were normalized with β-actin.
Collagen‑based 3D co‑culture
HUVEC-GFP and pericyte-dsRed were co-cultured at a 5:1 
ratio in a 3D bovine collagen type 1 (2 mg/ml) environment 
(Gibco), supplemented with EBM-2 medium (Lonza), ascor-
bic acid, fibroblast growth factor, 2% FCS, SCF-1, SDF-1α, 
and IL-3 (i.e., co-culture medium), as previously described 
[20]. Images were taken 2 days after seeding to assess the 
sprouting capacities of ECs and at day 5, when lumenized 
micro-capillary structures are formed. Images were taken 
with fluorescence microscopy with a 2x objective. Images 
were analyzed based on the number of junctions, the num-
ber of tubules, and the tubule length using AngioSys 2.0 
software.
VE‑cadherin internalization assay 
and immunofluorescence
The internalization assay was performed at 48-h post-trans-
fection as previously described [9]. Briefly, HUVECs were 
grown on coverslips to confluence before labeling the cell 
surface-exposed VE-cadherin by incubation with mouse 
anti-human VE-cadherin (Supplementary Table 3) at 4 °C 
for 1 h. Movement of labeled VE-cadherin was monitored 
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by placing the cells at 37 °C for 1 h, in basal medium with 
or without VEGF (50 ng/ml; Preprotech), after which the 
cells were either washed with PBS (PBS supplemented with 
1.8 mM CaCl2 and 1 mM MgCl2) or with a mildly acidic 
buffer [2 mM PBS-glycine (pH 2.0), 15 min] to remove 
membrane-bound antibodies and reveal the internalized 
labeled VE-cadherin. Cells were fixed with 4% paraformal-
dehyde for 30 min, followed by a blocking and permeabiliza-
tion step for 30 min in PBS with 1% BSA and 0.5% Triton-
X. Secondary antibody (Supplementary Table 3) incubation 
was performed for 1 h at room temperature, followed by a 
30-min incubation step to label cytoskeletal F-actin with 
rhodamine phalloidin (Supplementary Table 3). For labe-
ling of Rab proteins (Supplementary Table 3), an extra pri-
mary antibody step was performed after fixation instead of 
labeling cytoskeletal F-actin. DAPI was used as a nuclear 
counterstain. Images of fluorescent-labeled markers were 
obtained with a Leica TCS SP8 X microscope and a 63x 
oil immersion objective lens. 3D images were obtained by 
scanning multiple XY planes in the Z direction with a depth 
of ± 10 µm. Serial pictures along the Z-axis were combined 
to create a stacked XY image. The total internalized VE-
cadherin area was determined by using ImageJ 1.47v.
Morpholino injection in developing zebrafish larvae
Zebrafish (Danio rerio) were maintained under stand-
ard laboratory conditions. Morpholinos (MO) against the 
zebrafish orthologue of CMTM4 were obtained from Gene 
Tools (Philomath, USA) and suspended in Danieau buffer 
[58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM 
Ca(NO3)2, 5.0 mM HEPES pH 7.6 containing 0.2% phenol 
red]. Different doses of the MO were injected into single-cell 
stage zebrafish embryos as previously described [21]. The 
sequences are listed in Supplementary Table 4.
Flow cytometry
CMTM4-silenced HUVECs were seeded at a density of 
50 × 103 cells/well in co-culture medium. After 24, 48, and 
72 h, cells were harvested for proliferation and apoptosis 
analysis. Each harvested sample was stained with Propidium 
Iodide (PI) and Annexin V (BD Pharmingen) according to 
the manufacturer’s protocol and analyzed by flow cytometry 
(BD Facs Canto). Cells were counted for 2 min at medium 
speed to determine the average cell amount. Cell cycle anal-
ysis was conducted after the cells were cultured for 48 h at 
37 °C in 5% CO2 and fixed overnight in 70% ethanol at 4 °C. 
Cells were washed with ice-cold PBS and were stained with 
PI and treated with 0.5 mg/ml RNase for 30 min at 37 °C 
before analysis by flow cytometry.
Migration assay
HUVECs were seeded at a density of 75 × 103 cells/well in a 
24-well plate and after 24 h. EC migration was assessed 24-h 
post-transfection by scratching the HUVEC layer using a 
200-µl-pipette tip. Loose cells were removed by a PBS wash. 
Images were taken at t = 0, t = 4, and t = 8 h, after which the 
scratch area reduction was determined using Adobe Photo-
shop CS6.
Intracellular immunostaining
HUVECs were seeded at a density of 10 × 104 cells/well 24 h 
prior to transfection. Cells were fixed 48-h post-transfection 
with 4% paraformaldehyde for 30 min, followed by a block-
ing and permeabilization step for 30 min in PBS with 1% 
BSA and 0.5% Triton-X. This was followed by incubation 
with a primary and secondary antibody (Supplementary 
Table 3) at room temperature for 1.5 and 1 h, respectively. 
Cytoskeletal F-actin was labeled with rhodamine phalloidin 
and DAPI was used as a nuclear counterstaining. Images 
of fluorescent-labeled markers were obtained with a Leica 
TCS SP8 X microscope and a 63x oil immersion objective 
lens. For quantification of the total area, 3D images were 
obtained by scanning multiple XY planes in the Z direction 
with a depth of ± 10 µm. Serial pictures along the Z-axis 
were combined to create a stacked XY image that was further 
analyzed using ImageJ 1.47v.
Transendothelial resistance measurements
HUVECs were transfected with CMTM4 siRNA or adeno-
virus 24 h prior to seeding on a 0.1% gelatin permeable fil-
ter insert (0.4 µm pore, Falcon). Before the experiment, the 
resistance (Rblank) was measured by placing unseeded inserts 
in an Endohm-SNAP chamber filled with 5 ml of EGM-2 
medium (World Precision Instruments, Berlin). The chamber 
was coupled to an EVOMX resistance meter (World Pre-
cision Instruments, Berlin). The transendothelial electrical 
resistance (TEER) was measured daily to monitor resistance 
buildup during growth towards full confluence. At day 2, 
confluent monolayers were treated with 1 U/ml thrombin for 
20 min during which the TEER was measured every 5 min. 
After 20 min, the thrombin solution was washed away and 
replaced with normal medium. TEER was measured every 
15 min during the restoration phase for 2 h.
Statistical analysis
The statistical analyses were performed using Graphpad 
Prism version 7.02. To test if values came from a Gauss-
ian distribution, the D’Agostino–Pearson omnibus or 
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Fig. 1  CMTM4-targeting siRNA induces significant and spe-
cific silencing of CMTM4 expression. a Gene expression levels of 
CMTM4 in HUVECs transfected with CMTM4-targeting siRNA 
(siCMTM4), non-targeting siRNA (siSHAM), and in non-transfected 
HUVECs (control). b Representative Western blot of CMTM4 and 
β-actin protein levels in siCMTM4, siSHAM, and control HUVECs. 
Shown is a representative blot of 3 blots. c Gene expression levels 
of CMTM family members in siCMTM4, siSHAM, and control 
HUVECs. For a and c, gene expression levels were normalized to 
β-actin (AU); values are mean ± SEM, **P < 0.01; N ≥ 8 qPCRs
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Shapiro–Wilk normality test were used. The unpaired t-test 
and the ordinary one-way ANOVA test were used if the val-
ues were normally distributed. In case the values did not 
pass the normality test, either the Mann–Whitney test or 
Kruskal–Wallis were used as non-parametric tests. P ≤ 0.05 
was accepted as statistically significant. Values are shown 
as mean ± SEM.
Results
CMTM4 expression is essential for vascular growth 
in an in vitro 3D angiogenesis assay
The function of CMTM4 was investigated in vitro using 
siRNA-mediated silencing in HUVECs. Both qPCR and 
Western blot analysis confirmed efficient silencing of 
CMTM4 in cells transfected with two different siRNA sets 
specific for CMTM4 (siCMTM4 set 1 and set 2), compared 
to untreated cells (control) and cells transfected with a pool 
of non-targeting siRNA sequences (siSHAM) (Fig. 1a, b). 
The mRNA levels of the other CMTM family members were 
not significantly downregulated by both CMTM4 targeting 
siRNA sets when comparing siCMTM4 versus siSHAM, 
indicating that the siRNA-mediated silencing was specific 
for CMTM4 (Fig. 1c).
Next, the angiogenic potential of these CMTM4-silenced 
HUVECs was assessed in vitro in a 3D angiogenesis assay 
developed for studying the formation of lumenized micro-
capillary structures [22]. In this assay, GFP-expressing 
HUVECs and dsRED-expressing pericytes directly interact 
in a collagen type I matrix. After 1 day of co-culture, EC 
sprouting and tubule formation can be observed and these 
neovascular structures are stabilized by perivascular recruit-
ment of pericytes. After 5 days, micro-capillaries with dis-
tinct luminal areas and pericyte coverage can be observed. 
Imaging and quantification of these vascular structures was 
conducted at day 2 and 5. This assay has been well vali-
dated in previous studies [23–25]. Endothelial silencing of 
CMTM4 severely impaired the formation of neovascular 
structures in the 3D angiogenesis assay when compared to 
control and siSHAM (Fig. 2a). Quantification revealed a 
significant reduction in the number of junctions, the number 
of tubules, and the total tubule length of HUVECs after both 
2 and 5 days of co-culture (Fig. 2b). In contrast, CMTM4 
silencing in pericytes did not affect tubule formation at 2 or 
5 days of co-culture (Supplementary Fig.1a–d).
Silencing of CMTM4 in developing zebrafish larvae 
inhibits intersomitic vessel growth
In order to evaluate CMTM4 function during in  vivo 
angiogenesis, the zebrafish orthologue of the gene was 
silenced in developing larvae of the transgenic zebrafish 
line Tg(fli1:eGFP)y1 by morpholino knockdown. CMTM4 
is highly conserved in the zebrafish genome and two mor-
pholinos were designed to target the CMTM4 zebrafish 
orthologue with knockdown based on the splice modifi-
cation principle of the pre-mRNA target. Injection with a 
morpholino construct that targeted the splice site located on 
CMTM4 intron 2-exon 3 (i2-e3) affected intersomitic vessel 
(ISV) formation versus uninjected larvae at 24 h post fertili-
zation (Fig. 3a). Phenotype quantification showed in the 3 ng 
i2-e3 morpholino group that 36% of larvae displayed defects 
in ISV formation versus 0% in the control group. Injection 
with 6 ng i2-e3 increased the number of larvae with affected 
ISVs to 48% (Fig. 3b). In line with these findings, injection 
of the second morpholino construct that targeted the splice 
site on CMTM4 intron 1-exon 2 (i1-e2) affected ISV forma-
tion in 56% of the larvae in the i1-e2 group versus 0% in the 
control population (Supplementary Fig. 2a, b). These data 
clearly demonstrate a negative effect of CMTM4 silencing 
on angiogenesis in developing zebrafish larvae in vivo.
Effect of CMTM4 on cell cycle progression, 
migration, and proliferation
Previous studies in HeLa and clear cell renal cell carcinoma 
cells imply that CMTM4 functions as a tumor suppressive 
gene, with expression of CMTM4 leading to cell migration 
and inhibition of cell proliferation via G2/M phase accu-
mulation [14, 15]. We investigated the effects of CMTM4 
silencing in HUVECs on these parameters. CMTM4 silenc-
ing using either siRNA set 1 or 2 did not affect cell prolif-
eration as shown by comparison with siSHAM-treated and 
non-treated control groups based on cell count and PI analy-
sis of the G0/G1-phase and G2 phase in fixed cells (Supple-
mentary Fig. 3a, b). Migration capacity was also assessed by 
scratch assay and showed a significant decrease in response 
to CMTM4 silencing by set 2, but not by set 1, in HUVECs 
compared to siSHAM-treated or non-treated controls after 4 
and 8 h of migration (Supplementary Fig. 3c–e).
Next, we investigated the effects of CMTM4 overexpres-
sion on the same parameters. HUVECs were transfected with 
a recombinant adenovirus that encodes for human CMTM4 
Fig. 2  CMTM4 silencing is essential for vascular growth in vitro. a 
Representative immunofluorescent images taken at ×2 magnifica-
tion (upper row) and zoomed-in images (three lower rows) of GFP-
labeled HUVECs (green) and dsRED-labeled pericytes (red) cultured 
for 5 days in a 3D collagen matrix, in which the HUVECs-GFP were 
transfected with either CMTM4-targeting siRNA (siCMTM4) or non-
targeting siRNA (siSHAM) or not transfected (control). Scale bar rep-
resents 1 mm for the upper row and 0.25 mm for the three lower rows. 
b Quantification of the number of junctions, number of tubules, and 
total tubule length of siCMTM4, siSHAM, and control HUVECs at 
day 2 and 5 of co-culture. Values are mean ± SEM, **P < 0.01 com-
pared to all other conditions; N ≥ 6 co-cultures, ± 7 images each
◂
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cDNA (adCMTM4). qPCR analysis validated significant 
transgenic expression of CMTM4 in HUVECs compared to 
HUVECs transfected with sham virus (adSHAM) (Fig. 4a). 
In contrast with CMTM4 silencing, cell count and cell cycle 
progression were decreased in adCMTM4 HUVECs versus 
adSHAM or non-transfected groups, as shown by reduced 
cell count and an increase of cells in G0/G1 versus G2 phase 
(Fig. 4b, c). However, overexpression of CMTM4 did not 
affect migration capacity of HUVECs (Fig. 4d–f). These 
findings indicate that increased levels of CMTM4 limit cell 
proliferation, but do not affect cell migration.
CMTM4 colocalizes with endocytic vesicle structures 
and VE‑cadherin in adherens junctions
In a recent study, we revealed that CMTM3 is mainly local-
ized in the cytosol, where it is involved in regulating the 
early endocytosis of the AJ protein VE-cadherin [19]. There-
fore, we evaluated in this study the intracellular function of 
CMTM4 in ECs. Western blot analysis demonstrated that 
CMTM4 was mainly present in the soluble cytosolic frac-
tion and not in the insoluble more actin enriched fraction of 
the HUVEC lysates (Fig. 5a). Similarly, VE-cadherin was 
mainly enriched in the soluble fraction (Fig. 5a).
Double immunofluorescent staining of CMTM4 with dif-
ferent markers of intracellular vesicular transport compart-
ments showed limited colocalization with early endosome 
markers EEA1 and Clathrin (Fig. 5b–d). In contrast, exami-
nation of CMTM4 with markers of recycling vesicles 
showed significant colocalization between CMTM4 and 
Rab4, but not Rab11 (Fig. 5b, e, f). Furthermore, colocali-
zation between CMTM4 and Rab7, a marker for vesicles 
destined for the lysosome pathway, was also significantly 
increased compared to EEA1, clathrin, and Rab11 (Fig. 5b, 
g). These findings indicated that CMTM4 was colocalized 
in (Rab4 marked) recycling and (Rab7 marked) lysosome-
destined vesicles and may contribute to recycling and lyso-
some activity in the process of endocytosis. Further analysis 
of CMTM4 intracellular localization showed cytosolic and 
cell–cell junction localization of the protein. Dual immu-
nostaining analysis demonstrated that the CMTM4 signal 
colocalized with VE-cadherin, both at the AJs and in cyto-
solic vesicle structures (Fig. 5b, h). Transgenic overexpres-
sion of CMTM4 in ECs appeared to alter the junctional 
pattern of VE-cadherin into plaque-like structures (Fig. 5i). 
Studies have shown that Junction-Associated-Intermit-
tent-Lamellipodia (JAIL) structures appear at established 
endothelial junctions and induce an overlap with the plasma 
membrane of the neighboring cell, forming subsequent VE-
cadherin plaques that, after retraction of JAIL, are incorpo-
rated into the junctions [26, 27]. Overexpression of CMTM4 
did not affect the total VE-cadherin+ area (Fig. 5j). Similarly, 
Western blot analysis of adCMTM4 or adSHAM-transfected 
HUVECs showed no difference in total protein concentration 
of VE-cadherin (Fig. 5k).
Fig. 3  Morpholino silenc-
ing of CMTM4 in develop-
ing zebrafish larvae induces 
defects in intersomitic vessels. 
a Tg(fli1:eGFP)y1 larvae at 24 h 
post fertilization, anterior to the 
right, lateral view. Defects in 
intersomitic vessel (ISV) forma-
tion was observed in the trunk 
region in specimens injected 
with morpholinos targeting the 
splice site of i2-e3 of CMTM4 
(indicated as i2-e3 CMTM4) 
compared with uninjected (UI) 
controls. The vasculature is 
highlighted by eGFP (green). 
Left-hand panels show ×2 mag-
nification images with 0.5 mm 
scale bar, right-hand panels 
show 10x images with 0.25 mm 
scale bar. b Quantification of 
ISV defect phenotype versus 
wildtype (WT) phenotype in 
i2-e3 injected group at different 
doses versus UI controls (UIC). 
Data represent percentage 
of counted larvae (~ 100 per 
group)
Angiogenesis 
1 3
Fig. 4  CMTM4 overexpression 
limits endothelial cell prolif-
eration, but does not affect cell 
migration. a Quantitative poly-
merase chain reaction (qPCR) 
of human CMTM4 expression 
in HUVECs transfected with 
different (5, 10, 25) virus parti-
cles per cell (VPC) of adeno-
virus containing an expression 
vector for CMTM4 cDNA 
(adCMTM4) or with sham virus 
containing an empty expres-
sion vector (adSHAM). Shown 
are target gene/house-keeping 
gene (β actin) ratios (AU). 
Mean ± SEM, ***P < 0.001 in 
comparison between adSHAM 
and adCMTM4 group of equal 
VPC; N = 4 qPCRs. b The 
number of cells counted at day 
of seeding (day 1), and at day 2, 
3, and 4 of cell proliferation in 
adCMTM4 HUVECs compared 
with adSHAM and non-trans-
fected controls. Shown is mean 
± SEM, N = 6; *P < 0.05. c Bar 
graphs showing the % of G0/
G1 and G2 phase cells at day 2 
after transfection in adCMTM4 
versus adSHAM HUVECs 
and non-transfected controls. 
Shown is mean ± SEM, 
*P < 0.05, #P < 0.10; N = 4. 
d Representative brightfield 
microscope images (x4 magni-
fication) of a scratch migration 
assay after 8 h of migration 
of adCMTM4 HUVECs 
compared to adSHAM and 
non-treated controls. Scale 
bar represents 100 µm. Bar 
graphs of the quantified results 
of the scratch migration assay 
showing the % area within the 
scratched region covered by 
adCMTM4 HUVECs compared 
to adSHAM and non-treated 
controls after 4 h (e) and 8 h 
(f). Shown is a dot plot with 
the distribution and mean, 
***P < 0.001; N = 2, 8 wells 
each
 Angiogenesis
1 3
Angiogenesis 
1 3
Quantification of EEA1, Clathrin, Rab4, Rab11, and 
Rab7 immunofluorescence signals showed that  EEA1+, 
 Rab4+, and  Rab11+ vesicles were significantly increased in 
adCMTM4 versus adSHAM-treated HUVECs and a similar 
trend was visible for  Rab7+ vesicles. In contrast, the amount 
of  Clathrin+ vesicles was not affected (Fig. 6a–e). These data 
indicate that CMTM4 enhances endocytosis processes in 
ECs.
CMTM4 regulates VE‑cadherin endocytosis 
and promotes endothelial barrier function 
of endothelial adherens junctions
The putative role of CMTM4 in endocytosis processing of 
VE-cadherin was evaluated with an internalization assay, 
where confluent HUVECs transfected with adSHAM or 
adCMTM4 were exposed to a low-temperature shock (1 h 
at 4 °C) followed by an 1-h incubation at 37 °C. Assessment 
of VE-cadherin in relation to the actin cytoskeleton showed 
a significant increase in colocalization in adCMTM4-treated 
versus adSHAM confluent HUVEC monolayers, as dem-
onstrated by an increase in Pearson correlation coefficient 
(Fig. 7a, b). This finding indicates that CMTM4 promotes 
VE-cadherin connections with the actin cytoskeleton that 
are vital for AJ stabilization.
Next, the role of CMTM4 in VE-cadherin endocytosis 
was assessed. For this, confluent adSHAM or adCMTM4 
HUVECs were incubated with VE-cadherin antibody at 
4 °C before an acid-wash treatment to remove all extracel-
lular VE-cadherin signal. Subsequent analysis following 1-h 
incubation at 37 °C with and without VEGFA stimulation 
showed a significant increase of internalized VE-cadherin 
Fig. 5  (continued)
Fig. 5  CMTM4 localizes with different vesicle compartments of 
the intracellular endocytosis pathway and VE-cadherin+ adherens 
junctions. a Representative Western blot of CMTM4, β-actin, and 
VE-cadherin protein levels in the soluble and insoluble cell lysates 
fraction of HUVECs. b Quantification of colocalization of CMTM4 
with VE-cadherin and endocytic compartment markers in confo-
cal micrographs based on M1 coefficient. Mean ± SEM, *P < 0.05, 
**P < 0.01, ***P < 0.001; N = 3, 5 fluorescent images each. Repre-
sentative ×63 magnification (upper row) and zoomed-in (lower row) 
confocal microscope images of HUVECs transfected with adCMTM4 
(VPC10), immunostained for CMTM4 (red) and EEA1 (green) 
(c) Clathrin (green) (d), Rab4 (green) (e), Rab11 (green) (f), Rab7 
(green) (g), and VE-cadherin (green) (h). Colocalization of CMTM4 
and endocytic compartment protein markers or VE-cadherin in over-
lay images is displayed in yellow. Scale bars represent 10 µm for the 
upper rows and 5 µm for the lower rows. i Representative immuno-
fluorescence microscope images of VE-cadherin (green) in adSHAM 
and adCMTM4 HUVECs (VPC10). White arrow marks the altered 
VE-cadherin junctional pattern into a plaque-like structure. Scale 
bar represents 10  µm. j Quantification of total VE-cadherin+ area 
per cell in adSHAM or adCMTM4-transfected HUVECs (VPC10). 
Mean ± SEM; N = 3, 5 fluorescent Z-stacks each. k Representa-
tive Western blot bands for total CMTM4, VE-cadherin, and β-actin 
expression of adCMTM4 and adSHAM HUVECs (VPC5). Shown is 
a representative blot of 2 blots
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Fig. 6  CMTM4 overexpression 
significantly upregulates the 
endothelial endocytic pathway. 
Quantification of area per cell 
in adCMTM4 and adSHAM-
transfected HUVECs (VPC10). 
Representative confocal 
micrographs (×63 magnifica-
tion) of HUVECs transfected 
with adCMTM4 and adSHAM 
(VPC10), immunostained 
(green) for EEA1 (a), Clathrin 
(b), Rab4 (c), Rab11 (d), and 
Rab7 (e). For all data dis-
played, mean ± SEM, #P < 0.1, 
**P < 0.01, ***P < 0.001; N = 3, 
5 Z-stacks each; scale bars 
represent 10 µm
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in adCMTM4 versus adSHAM conditions (Fig. 7c–e). The 
internalized VE-cadherin upon VEGF stimulation was pre-
sent in both  Rab4+ and  Rab7+ vesicles with significantly 
more  Rab4+ and  Rab7+ vesicles loaded with VE-cadherin 
in adCMTM4 HUVECs when compared to adSHAM 
HUVECs (Fig. 7f–h). In line with these findings, siRNA-
mediated knockdown of CMTM4 significantly decreased 
the signal of internalized VE-cadherin in siCMTM4-treated 
HUVECs with and without VEGFA stimulation (Fig. 7i–k). 
This effect of CMTM4 was dependent on Rab4, since adC-
MTM4 HUVECs transfected with siRNA specific for Rab4a 
(siRAB4a) also showed significantly less internalized VE-
cadherin when compared to siSHAM HUVECs. The trend 
was still visible under VEGF stimulation (Fig. 7l–n and Sup-
plementary Fig. 4a).
Findings so far indicate that CMTM4 could regulate 
the bio-availability of VE-cadherin at cell–cell AJs, which 
implies that it could impact endothelial barrier function. We 
used transendothelial electric resistance (TEER) measure-
ments to evaluate the response of HUVEC monolayers trans-
fected with adSHAM or adCMTM4 to thrombin-induced 
junction disruption. Basal levels (before thrombin stimula-
tion) of TEER were not affected by CMTM4 overexpression. 
However, the recovery of TEER post-thrombin stimulation 
was significantly increased in adCMTM4 conditions com-
pared to adSHAM (Fig. 8a–c). In line with these findings, 
basal TEER levels were similarly not affected by siRNA-
mediated silencing of CMTM4, but TEER recovery after 
thrombin removal was significantly decreased in siCMTM4 
versus siSHAM conditions (Supplementary Fig. 4a, b).
Discussion
In this study, we investigated the angiogenic potential of 
CMTM4 and evaluated in which molecular pathways 
CMTM4 is involved in ECs. The most important findings 
of this study are as follows: (1) CMTM4 silencing impairs 
vascular growth in an in vitro 3D angiogenesis assay. (2) 
Silencing of CMTM4 in developing zebrafish larvae inhibits 
intersomitic vessel growth. (3) Intracellular staining reveals 
that CMTM4 colocalizes with  Rab4+ and  Rab7+ vesicles, 
and with both membrane-bound and internalized VE-cad-
herin. (4) CMTM4 enhances the endothelial endocytic path-
way, in particular the Rab4 recycling pathway. (5) CMTM4 
also enhances VE-cadherin internalization and increases 
endothelial barrier function recovery.
Several previous studies have revealed that CMTM fam-
ily members can prevent growth and invasion of different 
cancer cell types [11–18]. CMTM4 has been reported to be 
frequently downregulated in clear cell renal cell carcinoma 
where it functions as a tumor suppressor. Thus, restoration 
of CMTM4 suppresses the tumorigenicity of these cancer 
cells, whereas knockdown of CMTM4 leads to enhanced 
tumor growth [14]. Furthermore, overexpression of CMTM4 
inhibits HeLa cell growth via G2/M phase accumulation 
[15]. In a recent study, we demonstrated that CMTM3 has a 
specialized function in ECs, where it is involved in the regu-
lation of early endocytosis of VE-cadherin during vascular 
growth [19]. However, the putative function of CMTM4 in 
endothelial endocytosis and the contribution of CMTM4 to 
the regulation of vascular permeability have not been elu-
cidated to date.
In the present study, we demonstrate that CMTM4 plays 
an important role in angiogenesis. Loss of CMTM4, as 
shown in vitro with a 3D vascular assay and in vivo with 
zebrafish larvae, results in a significant reduction of vas-
cular sprouting. ECs can actively modulate their junctional 
adhesive strength by regulating the amount of bioavail-
able VE-cadherin on the cell membrane. A reduction in 
membrane-bound VE-cadherin will result in microvascular 
destabilization that is required for EC migration and vascular 
sprouting. Vascular sprouting from pre-existing vessels is 
mediated by VEGFA by stimulating the endocytosis of VE-
cadherin [9]. Similar to CMTM3, we have shown that the 
angiogenic capacity of CMTM4 is associated with the regu-
lation of cell surface VE-cadherin. CMTM4 overexpression 
promotes the internalization of VE-cadherin, both at basal 
levels and in response to VEGFA stimulation. Vice versa, 
CMTM4 knockdown inhibits VE-cadherin internalization. 
In line with our findings, it has been shown that a reduction 
of VE-cadherin both in vitro and in vivo increases vascular 
permeability and stimulates vascular sprouting [4, 28].
After these initial stages of neovessel formation, VE-
cadherin is eventually required for the formation of a stable 
vasculature by preventing disassembly. This is demonstrated 
in VE-cadherin-deficient mice, who suffer from severe vas-
cular defects, resulting in death at mid-gestation [5, 6]. In 
line with those observations, our data indicate that CMTM4 
overexpression promotes VE-cadherin connections with the 
actin cytoskeleton that are vital for AJs stabilization. The 
VE-cadherin/catenin complex interacts with actin filaments 
to ensure adequate junction adhesion and barrier function. 
Usually, the boundaries between adjacent ECs display a 
stable linear morphology and are regulated by circumfer-
ential actin filaments. However, endothelial AJs are highly 
dynamic and reorganize continuously in response to external 
stimuli [27]. These linear cell–cell junctions can convert into 
dynamic discontinuous cell–cell junctions, characterized 
by the appearance of stress fibers and zigzagged junctions 
where VE-cadherin aligns with the end of these stress fib-
ers. Discontinuous junctions are characteristic for an acti-
vated and permeable endothelium [29]. Our data indicate 
that AJs are quickly restored in adCMTM4 HUVECs after 
a cold stimulus, showing a stable resting condition pattern 
with linear VE-cadherin junctions that colocalize with the 
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circumferential actin filaments. adSHAM HUVECs appear 
to be at a different stage of cell–cell junction remodeling 
in response to the cold stimulus, showing a zigzagged VE-
cadherin pattern and stress fibers. This discontinuous pat-
tern seen in adSHAM HUVECs will contribute to a rapid 
increase in endothelial permeability and subsequently a 
longer recovery phase. In concordance, TEER measurements 
reveal a fast recovery after thrombin-induced endothelial 
junction disruption in ECs with overexpression of CMTM4 
when compared to sham-treated cells, whereas knockdown 
of CMTM4 results in a lower recovery rate. Taken together, 
these results are consistent with the concept that CMTM4 
is responsible for a fast turnover of VE-cadherin from the 
plasma membrane and back, thereby regulating the junc-
tional adhesive strength of ECs and hence the endothelial 
barrier function.
The turnover of cell surface VE-cadherin involves endo-
cytic trafficking pathways, in which VE-cadherin is trans-
ferred into the cytosol in clathrin-coated vesicles and is 
further sorted for recycling or lysosomal trafficking routes, 
among others [7]. Cargo proteins can be recycled back to 
the plasma membrane through two distinct recycling path-
ways: The Rab4-mediated rapid recycling pathway and the 
Rab11-mediated slow endosome pathway [30]. Rapid recy-
cling occurs directly from the early endosomal compartment, 
whereas the slow recycling route involves protein cargo 
trafficking from either early endosomes or the trans-Golgi 
network through the pericentriolar recycling endosomal 
compartment, before returning to the cell surface [31, 32].
In the present study, we demonstrate that CMTM4 
strongly colocalizes with Rab4 and VE-cadherin, suggesting 
that CMTM4 is involved in regulating the rapid recycling 
of VE-cadherin back to the plasma membrane at AJs. Fur-
thermore, overexpression of CMTM4 significantly increases 
 Rab4+ vesicles in the cytosol, but does not increase the total 
protein amount of VE-cadherin, indicating that CMTM4 
regulates the localization, but not the synthesis or degra-
dation of VE-cadherin. It has been shown that overexpres-
sion of Rab4 increases the recycling of various receptors 
back to the cell surface. For example, Rab4 overexpression 
in CHO (Chinese Hamster Ovary) cells raises the number 
of transferrin receptors on the cell surface from 20 to 80% 
[33]. Recycling and activation of the β-Adrenergic recep-
tor is also enhanced by overexpression of Rab4 in cardiac 
myocytes [34]. Furthermore, Rab4 activation increases 
the expression of VE-cadherin at the cell surface of lung 
microvascular endothelial cells (LMVECs), whereas Rab4 
inhibition reduces VE-cadherin levels, thereby increasing 
vascular permeability [35]. More specifically, Rab4 activa-
tion enhances EC migration, adhesion, and tube formation 
[36]. As reported by these studies, silencing of Rab4a in 
HUVECs overexpressing CMTM4 reduces the internaliza-
tion of VE-cadherin, indicating that the effect of CMTM4 
is dependent on Rab4.
Besides Rab4, we show that CMTM4 overexpression also 
significantly enhances  Rab11+ and  EEA1+ vesicles in the 
cytosol. EEA1 colocalizes exclusively to early endosomes, 
from which cargo is further sorted into trafficking routes. 
Silencing of Rab11a in LMVECs prevents VE-cadherin 
Fig. 7  CMTM4 upregulates endocytosis and subsequent recycling 
of VE-cadherin. a Representative ×63 magnification (upper row) 
and zoomed-in (lower row) confocal microscope images of conflu-
ent HUVEC cultures that were immunostained for F-actin (red) and 
VE-cadherin (green) in adSHAM and adCMTM4-transfected cells 
(VPC10) that were exposed to low-temperature shock (1 h at 4  °C) 
followed by 1-h incubation at 37 °C. Adherens junctions were quicker 
restored in adCMTM4 condition versus adSHAM conditions (zig-
zagged VE-cadherin signal in adSHAM versus linear VE-cadherin 
junctions). Colocalization signal in overlay is in yellow. Scale bars 
represent 25 µm for the upper rows and 5 µm for the lower rows. b 
Quantification of the colocalization signal between VE-cadherin and 
F-actin in confocal micrographs based on normalized Pearson corre-
lation coefficient (Rr). Mean ± SEM, ***P < 0.001 versus adSHAM; 
N = 4, 5 Z-stacks each. c Representative confocal micrographs (×63 
magnification) of confluent adSHAM and adCMTM4 cultures 
(VPC10) labeled with VE-cadherin antibodies at 4  °C to track VE-
cadherin movement, followed by 37  °C incubation for 1 h with and 
without VEGFA stimulation. Surface bound VE-cadherin antibodies 
were removed by an acid-wash, before proceeding with immunostain-
ing for visualization of internalized VE-cadherin (green). Scale bar 
represents 10 µm. Quantification of internalized VE-cadherin area per 
cell in adSHAM and adCMTM4 HUVECs without VEGFA (d) and 
with VEGFA (e) stimulation. Mean ± SEM, **P < 0.01, ***P < 0.001 
versus adSHAM; N = 4, 5 Z-stacks each. f Representative zoomed-
in confocal micrographs (×63 magnification) of confluent adSHAM 
and adCMTM4 cultures (VPC10) labeled with VE-cadherin antibod-
ies at 4 °C to track VE-cadherin movement, followed by 37 °C incu-
bation for 1 h with and without VEGFA stimulation. Surface bound 
VE-cadherin antibodies were removed by an acid-wash, before pro-
ceeding with immunostaining for visualization of internalized VE-
cadherin (green) and either Rab4 or Rab7 (red). Scale bar represents 
5  µm. Quantification of colocalization of either Rab4 (g) or Rab7 
(h) with VE-cadherin in confocal micrographs based on M1 coef-
ficient. Mean ± SEM, *P < 0.05; N = 2, 5 fluorescent images each. i 
Representative confocal micrographs (×63 magnification) of conflu-
ent siSHAM and siCMTM4 cultures labeled with VE-cadherin anti-
bodies at 4  °C to track VE-cadherin movement, followed by 37  °C 
incubation for 1  h with and without VEGFA stimulation. Surface 
bound VE-cadherin antibodies were removed by an acid-wash, before 
proceeding with immunostaining for visualization of internalized 
VE-cadherin (green). Scale bar represents 10  µm. Quantification of 
internalized VE-cadherin area per cell in siSHAM and siCMTM4 
HUVECs without VEGFA (j) and with VEGFA (k) stimulation. 
Mean ± SEM, *P < 0.05 versus adSHAM; N = 2, 5 Z-stacks each. l 
Representative confocal micrographs (×63 magnification) of conflu-
ent siSHAM HUVECs and HUVECs transfected with Rab4a-target-
ing siRNA (siRAB4a) labeled with VE-cadherin antibodies at 4  °C 
to track VE-cadherin movement, followed by 37  °C incubation for 
1  h with and without VEGFA stimulation. Surface bound VE-cad-
herin antibodies were removed by an acid-wash, before proceeding 
with immunostaining for visualization of internalized VE-cadherin 
(green). Scale bar represents 10  µm. Quantification of internalized 
VE-cadherin area per cell in siSHAM and siRAB4a HUVECs with-
out VEGFA (m) and with VEGFA (n) stimulation. Mean ± SEM, 
**P < 0.01 versus adSHAM; N = 2, 7 Z-stacks each
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recycling and expression at the plasma membrane and 
blocks junctional reannealing after vascular inflammation 
[37]. CMTM4 does not colocalize with either EEA1 or 
Rab11, however, our findings do imply that the slow endo-
some pathway is activated as well in response to CMTM4 
overexpression. Sorting endosomes leaving the recycling 
pathways are organized in different Rab domains, created 
through the recruitment of specific effector proteins [30]. 
These recycling endosomes are composed of multiple 
combinations of Rab proteins, creating distinct endosome 
populations. Fast recycling is achieved by rapid sorting into 
 Rab4+ domains within one endosome and recycling slows 
down once the cargo arrives to the pericentriolar membranes 
consisting mainly of  Rab4+ Rab11+ domains [30, 38]. After 
Rab4 depletion,  Rab11+ vesicles fuse with the plasma mem-
brane to release the protein cargo [38]. Rab4 is not involved 
in exocytosis, but acts as a regulator in the formation of 
recycling vesicles from early endosomes, since removal of 
Rab4 strongly inhibits the formation of these vesicles [39]. 
Our findings imply that CMTM4 may function as an effector 
protein for creating  Rab4+ domains in rapid and slow recy-
cling endosome populations. CMTM4 may also serve as an 
adaptor protein for targeting and positioning VE-cadherin in 
these  Rab4+  recycling vesicles, since our findings indicate 
that CMTM4 is also involved in VE-cadherin endocytosis 
and recycling.
Instead of recycling back to the plasma membrane, VE-
cadherin can also be targeted to the lysosomal trafficking 
route for degradation. In our dataset, CMTM4 also local-
izes with Rab7, which is involved in the regulation of late 
endosomal trafficking to lysosomes [40]. Furthermore, 
overexpression of CMTM4 enhances  Rab7+ vesicles in the 
cytosol, indicating that the lysosomal trafficking route is 
also activated in response to CMTM4 overexpression. In 
line with these statements, CMTM4 stimulates the loading 
of  Rab4+ and  Rab7+ trafficking vesicles with internalized 
VE-cadherin.
In a recent paper, we have shown that family member 
CMTM3 regulates the endocytosis of VE-cadherin and 
localizes with EEA1 and Clathrin, both markers of the 
early endocytic pathway, but not with Rab4 [19]. This gen-
erates the perception that the CMTM family may play an 
important role in the endocytosis and recycling of VE-cad-
herin in ECs, with each member of the gene family having 
their own specialized function along the various endocytic 
trafficking routes. All 9 CMTM family members contain a 
MARVEL domain, which is characterized by a four trans-
membrane-helix architecture, that has been associated with 
proteins involved in vesicle trafficking [41]. In line with 
this finding, overexpression of CMTM8 in tumor cell lines 
enhances the endocytosis of the epidermal growth factor 
receptor (EGFR), whereas knockdown delays endocyto-
sis [42]. We assessed if there is a functional relationship 
between CMTM4 and CMTM3. HUVECs overexpressing 
both CMTM4 and CMTM3 trend toward internalizing 
more VE-cadherin compared to single CMTM overexpres-
sion, but it does not reach statistical significance. Both 
HUVECs with single and double CMTM overexpression 
do internalize significantly more VE-cadherin than sham-
treated cells, implying that CMTM3 and CMTM4 do not 
hinder each other in their function (Supplementary Fig. 6a, 
b, g). Normally, CMTM4 localizes both at the cytosol and 
cell border in ECs, whereas CMTM3 only localizes at the 
cytosol. This pattern does not change when silencing the 
Fig. 8  CMTM4 promotes res-
toration of endothelial electric 
resistance in thrombin-induced 
response. a Thrombin response 
(presented in fold change com-
pared with basal resistance of 
non-transfected group: Y axes) 
of confluent HUVEC monolay-
ers during (0–20 min) and after 
(20–120 min) thrombin (1 U/
mL) stimulation in adCMTM4 
and adSHAM conditions. At 
0 min, thrombin was added 
and after 20 min thrombin 
was removed (gray area). 
Mean ± SEM. N ≥ 4 per time 
series. Increase in resistance 
during recovery phase at 90 min 
(b) and 120 min (c) in adSHAM 
and adCMTM4 groups. 
Mean ± SEM, #P < 0.10 versus 
adSHAM; N ≥ 6
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other family member, implying that CMTM4 and CMTM3 
do not regulate each other’s localization (Supplementary 
Fig. 6c–f and h). Further studies are required to assess 
if other family members are involved in the endocytosis 
regulation of ECs.
In conclusion, we have identified in this study for the 
first time to our knowledge, a regulatory function for 
CMTM4 in angiogenesis. CMTM4 plays an important role 
in the turnover of surface VE-cadherin, thereby mediat-
ing endothelial barrier function and controlling vascular 
sprouting. Further studies are needed to elucidate the exact 
mechanism by which CMTM4 regulates the endocytosis 
and trafficking of EC surface proteins. Increasing our 
understanding of the regulators of endothelial endocytosis 
could help find novel therapeutic targets for the treatment 
of various diseases associated with vascular leakage, to 
block vascular growth in tumors, or to overcome the prob-
lem of poor vascularization in tissue engineering.
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